Sonoma Pharmaceuticals Inc. (SNOA)
Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA
Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA
📈 **POSITIVE** • High confidence analysis (82%) • Strong positive financial catalyst • High potential for stock growth **Sentiment:** Positive (87%) **Content type:** Financial